The Association between Post-COVID-19 Myocardial Infarction and Antiphospholipid Syndrome

Background: Post-COVID-19 introduces various health challenges, including myocardial infarction (MI) linked to inflammation and coagulation, raising concerns for antiphospholipid syndrome (APS) patients. Elevated APS-related antibodies in some COVID-19 patients underscore the need for a comprehensive understanding of this cardiovascular interplay. Objectives: To determine the association between Post-COVID-19 and Myocardial Infarction and Antiphospholipid Syndrome. Patients and methods: This case-control study at Qena University Hospital explored the relationship between post-COVID-19 MI and APS, considering immune responses, genetics, and coexisting factors. Criteria included COVID-19 history, and MI symptoms, excluding certain conditions. Assessments included PCR, inflammatory markers, troponin I, coagulation profile, and specific antibody tests to detect Anticardiolipin-IgG, Anticardiolipin-IGM, anti nuclear anibody (ANA), and Anti-Double Strand (anti-DS). Results: Gender differences weren't significant (p = 0.0691). Lab data showed significant ESR and CRP elevation in cases (p